Executive summary

The gender health gap is identified as both a systemic market failure and a significant capital allocation opportunity. Historically, health innovation has not been built around 51% of the population, creating underpriced opportunities in diagnostics, therapeutics, medtech, and data infrastructure. Closing this gap could unlock up to US$1 trillion in annual global GDP by 2040 and approximately US$24.8 billion per year in Australia. Correcting this market inefficiency is a source of both commercial return and health impact.

The opportunity is broad and includes women-specific conditions such as endometriosis and menopause, conditions that affect women disproportionately like autoimmune disease and Alzheimer’s, and conditions that affect women differently, including cardiovascular disease and diabetes. Enabling infrastructure, such as sex-disaggregated datasets and AI platforms, also represents a critical investment area. Investors have a short window, estimated at less than 10 years, to capture the first-mover advantage before sex- and gender-aware innovation is fully priced into the market.

Why closing the gender health gap should matter to investors

This research argues that the gender health gap is a design, data, and capital allocation failure that creates avoidable health costs. For investors, this is both a commercial opportunity and a risk management issue. Products built on incomplete evidence may face adoption, reimbursement, and competitive exposure as regulatory expectations shift. In Australia, the National Health and Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF) have embedded requirements for sex and gender consideration in funding schemes from 2026. This shift will change how health evidence is generated, disadvantaging companies that rely on male-default data.

The gender health gap: A design, research and capital failure

The gap refers to systematic differences in health outcomes, quality of care, and research evidence. It is driven by modifiable factors such as male-default research and non-disaggregated data. For example, endometriosis diagnosis in Australia can be delayed for 6 to 8 years, signalling a demand for better diagnostics and integrated care models. Similarly, women are less likely than men to receive bystander CPR in public, often due to design and training gaps regarding the existence of breasts. In oncology, right-sided colon cancer is more common in women and harder to detect, meaning technologies designed around male-default assumptions may miss value and create liability risks.

Where are the investment opportunities?

Investment opportunities are categorised into three buckets. First, women-specific markets addressing high unmet needs in fertility and maternal health. Second, existing markets redesigned for women, which include cardiovascular disease and mental health, where larger market sizes and clearer comparables exist. Third, infrastructure and enablers, such as clinical trial tools and AI platforms, which help future-proof products as evidence standards change. Returns are distinguished by commercial value (revenue, margins, IPOs), economic value (productivity, avoided costs), and social/health value (earlier diagnosis, improved quality of life). Recent data indicates a maturing market, with US$100B+ in realised value across women’s health over the last 25 years.

Australia: Strong foundations, scalability needed

Australia possesses the ingredients for a significant women’s health innovation market, including world-class research and a growing startup ecosystem. Recent activity includes the agreement by Hims & Hers to acquire the Australian digital health company Eucalyptus in 2026. Additionally, UNSW Founders reported a twofold increase in women’s health startup applications in 2026 compared to the previous year. However, the pathway from research to commercial scale remains uneven, requiring better visibility of credible opportunities and stronger validation pathways.

What Australian investors told us

A survey of 14 respondents and seven in-depth consultations revealed that while awareness of gender equity is high, practice remains uneven. Fewer than 25% of respondents have structured due diligence (DD) questions on gender data. Investors noted that a ‘niche’ perception persists due to the conflation of women’s health with reproductive care. A primary constraint is the lack of mid-stage capital, specifically a dedicated Series B/C fund in Australia to keep Phase 2 and 3 trials in-country. The typical timeline from angel-stage to exit is estimated at 10-15 years, which is often mismatched with standard fund lifecycles.

From interest to investment: What needs to happen next

The action plan for investors includes adopting a broader definition of women’s health and adding sex and gender questions into due diligence. Investors should assess whether trial, product, and user data are sex-disaggregated and educate investment committees on the commercial distinctions of the sector. The ecosystem must build a national expert map and improve access to clinician-researchers. Finally, there is a need to increase early-to-mid-stage health capital for clinical validation and regulatory strategy, supporting patient capital for longer life sciences timelines and exploring new financial models specific to women’s health markets.